Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01887366 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects
A Phase 2 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 208
- Enrollment target
NCT01887366 is a Phase 2 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 208 participants.
The verdict
NCT01887366, a Phase 2 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 208 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the efficacy and safety of TV-1380 \[Recombinant human serum albumin (HSA) mutated butyrylcholinesterase (AlbuBChE)\] in facilitating abstinence in cocaine-dependent subjects.
Interventions
- DRUG Placebo
- DRUG TV-1380 150 mg
- DRUG TV-1380 300 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2013-06 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01887366
The ClinicalTrials.gov registry entry for NCT01887366 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01887366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01887366 about?
NCT01887366 is a clinical study titled "Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects". The primary objective of this study is to assess the efficacy and safety of TV-1380 \[Recombinant human serum albumin (HSA) mutated butyrylcholinesterase (AlbuBChE)\] in facilitating abstinence in cocaine-dependent subjects.
What is the current status of trial NCT01887366?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 208 participants. The study started on 2013-06. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01887366?
The interventions under investigation include: Placebo (DRUG), TV-1380 150 mg (DRUG), TV-1380 300 mg (DRUG).
Who is sponsoring clinical trial NCT01887366?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.